

Quentin A Hill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2695061/publications.pdf>

Version: 2024-02-01

43
papers

1,678
citations

393982

19
h-index

301761

39
g-index

52
all docs

52
docs citations

52
times ranked

1790
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. <i>Blood Reviews</i> , 2020, 41, 100648.	2.8	267
2	The diagnosis and management of primary autoimmune haemolytic anaemia. <i>British Journal of Haematology</i> , 2017, 176, 395-411.	1.2	164
3	Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. <i>Intensive Care Medicine</i> , 2019, 45, 977-987.	3.9	100
4	Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. <i>British Journal of Haematology</i> , 2017, 177, 208-220.	1.2	93
5	Autoimmune hemolytic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 382-389.	0.9	93
6	Real-world experience with caplacizumab in the management of acute TTP. <i>Blood</i> , 2021, 137, 1731-1740.	0.6	93
7	Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 189, 1038-1043.	1.2	89
8	Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. <i>Blood Advances</i> , 2017, 1, 1159-1166.	2.5	84
9	Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. <i>Blood Advances</i> , 2019, 3, 1897-1906.	2.5	69
10	Novel insights into the treatment of complement-mediated hemolytic anemias. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987332.	1.1	65
11	Fatigue in immune thrombocytopenia. <i>British Journal of Haematology</i> , 2015, 170, 141-149.	1.2	62
12	Intensify, resuscitate or palliate: Decision making in the critically ill patient with haematological malignancy. <i>Blood Reviews</i> , 2010, 24, 17-25.	2.8	53
13	Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 385, 885-895.	13.9	53
14	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. <i>Tumor Biology</i> , 2017, 39, 101042831769979.	0.8	45
15	Immune thrombocytopenia: improving quality of life and patient outcomes. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 369-384.	0.7	44
16	Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 190, 933-938.	1.2	38
17	Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data. <i>Critical Care</i> , 2018, 22, 326.	2.5	37
18	Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group study. <i>Leukemia and Lymphoma</i> , 2012, 53, 282-288.	0.6	30

#	ARTICLE	IF	CITATIONS
19	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. <i>BMJ Open</i> , 2018, 8, e024427.	0.8	20
20	Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. <i>Acta Haematologica</i> , 2021, 144, 418-426.	0.7	17
21	A fatal case of transplantation-mediated alloimmune thrombocytopenia following liver transplantation. <i>Hematology</i> , 2017, 22, 162-167.	0.7	13
22	Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia. <i>American Journal of Transplantation</i> , 2021, 21, 4095-4097.	2.6	13
23	A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK. <i>British Journal of Haematology</i> , 2022, 196, 351-355.	1.2	12
24	How does dapsone work in immune thrombocytopenia? Implications for dosing. <i>Blood</i> , 2015, 125, 3666-3668.	0.6	11
25	Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?. <i>American Journal of Transplantation</i> , 2017, 17, 796-802.	2.6	11
26	The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2019, 185, 410-417.	1.2	10
27	Recapitulation of erythropoiesis in congenital dyserythropoietic anemia type I (CDA-I) identifies defects in differentiation and nucleolar abnormalities. <i>Haematologica</i> , 2021, 106, 2960-2970.	1.7	10
28	Genetic and functional insights into CDA-I prevalence and pathogenesis. <i>Journal of Medical Genetics</i> , 2021, 58, 185-195.	1.5	9
29	A combination of two novel alpha globin variants Hb Bridlington (<i>HBA1</i>) and Hb Taybe (<i>HBA2</i>) resulting in severe hemolysis, pulmonary hypertension, and death. <i>Hematology</i> , 2015, 20, 50-52.	0.7	8
30	Disappointing response to dapsone as second line therapy for primary ITP: a case series. <i>Annals of Hematology</i> , 2015, 94, 1053-1054.	0.8	7
31	A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , 2018, 180, 591-594.	1.2	7
32	Towards better blood transfusion - recruitment and training. <i>Transfusion Medicine</i> , 2009, 19, 2-5.	0.5	6
33	Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program. <i>Blood</i> , 2018, 132, 736-736.	0.6	6
34	Autoimmune hemolytic anemia. <i>Hematology</i> , 2015, 20, 553-554.	0.7	5
35	Developing the evidence base for the management of autoimmune haemolytic anaemia (AIHA): the UK experience. <i>British Journal of Haematology</i> , 2021, 192, e54-e57.	1.2	5
36	Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. <i>Advances in Therapy</i> , 2021, 38, 5791-5808.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Incidence of adult primary immune thrombocytopenia in England – An update. <i>European Journal of Haematology</i> , 2022, 109, 238-249.	1.1	5
38	Autoimmune haemolytic anaemia. <i>ISBT Science Series</i> , 2016, 11, 85-92.	1.1	4
39	Immune thrombocytopenia – in defence of the platelet count. <i>British Journal of Haematology</i> , 2018, 182, 128-130.	1.2	3
40	The Psychometric Properties of the ITP Life Quality Index Assessed in a Large Multinational "Real-World" Cohort of Immune Thrombocytopenia Patients. <i>Blood</i> , 2019, 134, 386-386.	0.6	3
41	Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. <i>European Journal of Cancer</i> , 2022, 162, 158-160.	1.3	3
42	Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study. <i>Blood</i> , 2018, 132, 2426-2426.	0.6	1
43	Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level. <i>British Journal of Haematology</i> , 2022, , .	1.2	0